1. Home
  2. Investing
  3. Stocks
  4. USA
  6. Gemini Therapeutics Inc (GMTX)
  7. Quote


Gemini Therapeutics Stock Price

-0.22 (-8.43%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 125,715
Bid Price 2.20
Ask Price 2.40
News -
Day High 2.67


52 Week Range


Day Low 2.30
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Gemini Therapeutics Inc GMTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.22 -8.43% 2.39 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.67 2.30 2.67 2.39 2.61
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,924 125,715 $ 2.49 $ 313,473 - 2.30 - 19.085
Last Trade Time Type Quantity Stock Price Currency
18:23:19 2 $ 2.44 USD


Draw Mode:

Gemini Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 103.04M 43.11M 22.15M $ - $ - -0.60 -1.80
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 176.95k 0.30%

more financials information »

Gemini Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GMTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.993.102.302.68118,077-0.60-20.07%
1 Month3.864.052.303.26120,685-1.47-38.08%
3 Months5.085.162.303.92131,757-2.69-52.95%
6 Months11.9112.902.305.89324,674-9.52-79.93%
1 Year12.1519.0852.308.36295,009-9.76-80.33%
3 Years12.1519.0852.308.36295,009-9.76-80.33%
5 Years12.1519.0852.308.36295,009-9.76-80.33%

Gemini Therapeutics Description

Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel therapeutic compounds to treat genetically defined AMD. Its candidate, GEM103, is a recombinant form of the Complement Factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health.

Your Recent History
Gemini The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.